Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer beat fourth-quarter estimates as Covid sales fell, pointing to obesity trial progress and cost cuts in its post-Covid ...

Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call ...

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Pfizer's fourth-quarter profits exceeded expectations, driven by strong demand for older drugs despite declining COVID-19 ...

Pfizer highlighted another fall in quarterly revenues tied to Covid-19 products, and $4.4 billion in asset impairments ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...